The Efficacy and Safety of Tenofovir Amibufenamide to Treat Low-level Viraemia After Entecavir Treatment

Inclusion Criteria:

1. Must be able to understand and sign a written informed consent, which must be obtainedprior to screening.
2. Male and non-pregnant, non-lactating female subjects who have reached the age of 18-65years (based on the date of signed informed consent). Female subjects of childbearingage with a negative serum pregnancy test.
3. Documented signs of chronic HBV infection (e.g., HBsAg positive for more than 6months.
4. Subjects treated with ETV over 1 year will be able to be enrolled in the study.
5. Subjects with 20 ≤ HBV-DNA < 2000 IU/mL at screening (including intermittent andcontinuous low-level viraeima).
6. Must be willing and able to comply with all study requirements.

Exclusion Criteria:

1. Female patients who are pregnant or breastfeeding or who plan to become pregnantduring the study period.
2. Men and women of childbearing potential who are unwilling to use an "effective" methodof contraception as defined in the protocol during the study period.
3. Co-infection with HAV HCV, HIV, HDV or HEV; or co-infection with autologous liver,metabolism-related fatty liver, or drug-induced liver injury.
4. Diagnosis of hepatocellular carcinoma by imaging (with evidence of hepatocellularcarcinoma)
5. Patients who have received a solid organ or bone marrow transplant
6. History of malignancy within 5 years prior to screening, except for specific tumorscured by surgical resection (basal cell dermal skin cancer, etc.); patients evaluatedfor probable malignancy were ineligible.
7. Currently receiving treatment with immunomodulators (e.g., corticosteroids),investigational drugs, nephrotoxic drugs, or drugs capable of regulating renalexcretion. Drugs that modulate renal excretion.
8. Renal, cardiovascular, pulmonary, or neurological disease that is considered severe bythe investigator.
9. Severe bone disease (e.g., osteochondrosis, chronic osteomyelitis, osteogenesisimperfecta, chondromalacia) or multiple fractures.
10. Subjects receiving a contraindicated combination drug (subjects receiving acontraindicated drug require a minimum 30-day washout period) and knownhypersensitivity reactions to study drugs, metabolites or formulation excipients.
11. Current alcohol or drug abuse that, in the investigator's judgment, may interfere withthe subject's compliance with study requirements.
12. Any other clinical condition that, in the opinion of the investigator, would renderthe subject unsuitable for the study or unable to comply with the dosing requirementsmedical condition or prior treatment.
13. Prior or existing clinical liver failure (Child-Pugh score ≥ grade B).